AnaptysBio, Inc. (NASDAQ: ANAB) is a Healthcare company (Biotechnology) with a market capitalization of $1.4B. The Maz Rating grades it against the other companies in its sector.
AnaptysBio, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $45.61, AnaptysBio, Inc. trades at 7.1x trailing earnings, 7.0x sales and 65.1x book value, with an EV/EBITDA of 16.0. Over the last twelve months it generated about $192M of revenue and $190M of net income. It runs an operating margin of 34.6% and a net margin of 96.3%. It shows return on equity of 907.0%, return on invested capital of -1014.5% and a free cash flow yield of 2.7%. On the balance sheet: a debt-to-equity ratio of 0.60 and a current ratio of 8.40. Over the past 52 weeks the share price ranged from $22.07 to $72.36, with a beta of 0.51.
AnaptysBio, Inc. does not currently pay a dividend.
23 Wall Street analyst ratings cover the stock: 17 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, AnaptysBio, Inc. (ANAB) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 10.2% / 30% · Interest income / Revenue 4.75% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 10.2% / 33% · Receivables / Mkt Cap (36m) 2.28% / 49% · Interest income / Revenue 4.75% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 10.2% / 33.33% · Receivables / Mkt Cap (24m) 2.28% / 33.33% · Interest income / Revenue 4.75% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 60.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 69.4% / 33.33% · Receivables / Avg Assets (4Q) 9.25% / 33.33% · Interest income / Revenue 4.75% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 49.8% / 33.33% · (Cash+Recv) / Total Assets 60.9% / 33.33% · Interest income / Revenue 4.75% / 5% | Fail |
It depends on the standard you follow. As of September 2026, AnaptysBio, Inc. (ANAB) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. AnaptysBio, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 4.75% of each dividend: AnaptysBio, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.